Alnylam Pharmaceuticals
ALNY
#634
Rank
ยฃ24.92 B
Marketcap
ยฃ192.51
Share price
-0.44%
Change (1 day)
63.40%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -ยฃ0.19 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ2.24 Billion. , an increase over its 2023 earnings that were of -ยฃ0.25 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -ยฃ0.19 Billion-24.59%
2023 -ยฃ0.25 Billion-67.84%
2022 -ยฃ0.76 Billion36.93%
2021 -ยฃ0.56 Billion-8.04%
2020 -ยฃ0.6 Billion-15.66%
2019 -ยฃ0.71 Billion12.23%
2018 -ยฃ0.64 Billion62.91%
2017 -ยฃ0.39 Billion17.78%
2016 -ยฃ0.33 Billion43.44%
2015 -ยฃ0.23 Billion60.69%
2014 -ยฃ0.15 Billion98.2%
2013 -ยฃ72.11 Million
2011 -ยฃ42.53 Million27.48%
2010 -ยฃ33.37 Million-10.92%
2009 -ยฃ37.46 Million95.77%
2008 -ยฃ19.14 Million
2006 -ยฃ30.65 Million-9.13%
2005 -ยฃ33.73 Million34.74%
2004 -ยฃ25.04 Million36.79%
2003 -ยฃ18.3 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ0.47 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.70 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.10 B-154.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ91.43 Million-49.96%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ32.1 Million-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.58 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ6.16 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ0.22 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel